Radioactive Diagnostic Agent Market Demand, Insights and Forecast up to 2024

Posted by Aman Jaiswar on October 14th, 2019

Radioactive agents are the nucleus of an unstable atom which emits radiations such as alpha, beta, gamma and X-rays and loses its energy. Radioactive diagnostic agents are mainly used to detect abnormalities and malfunction of specific tissue or organ in a body. Diagnostic techniques include medicine which are combined with radiotracers, which emit gamma rays from radiotracers within the body. These tracers are generally short half-lives isotopes linked to chemical compounds which goes through specific physiological processes.

Radioactive agents are important in the diagnosis as well as therapy of specific disease or defect in the body. Such radioactive agents are majorly used in cancer therapy. Moreover, number of biological studies are carried out with help of radioisotopes such as molecular biology, cell biology and structural biology. Radioactive agents are generally of two types: radioisotopes and radiotracers. Radioactive diagnostic agent are extremely helpful in the detection of internal organ complications. Radioisotopes are also widely used in scientific research laboratories, to determine metabolic processes in small animals as well as to study the pharmacokinetics of drugs.

Global Radioactive Diagnostic Agent Market has been segmented by product, applications, end users and geography. In terms of product, radioactive diagnostic agent has been categorized into radioisotopes and radiotracers. Based on the application, radioactive diagnostic agent market are segmented into single-photon emission computed tomography (SPECT) and Positron emission tomography (PET). Single-photon emission computed tomography is further sub-segmented into tumor imaging, Infection imaging, thyroid imaging, bone scintigraphy, internal organ functions, cardiac function and brain imaging.

To obtain all-inclusive information on forecast analysis of Global Radioactive Diagnostic Agent Market, Request a PDF Brochure Here

Positron emission tomography is also further sub-segmented into oncology, brain function, heart function, drug development, pharmacokinetics studies, Infectious diseases detection, neuroimaging and musculo-skeletal imaging. Moreover there are various other applications of the diagnostic agents which depends on the disease and illness of the patient. Majorly radioactive agents are used to detect tumor and cancerous cells and majorly used with positron emission tomography (PET). The end user for the radioactive diagnostic agent market include hospitals, nursing facilities, long term care centers, diagnostic imaging centers, pharmaceutical companies, research centers and many others.

The major players operating in this market include GE healthcare, Cardinal Health, Mallinckrodt, Eli Lilly and Company, Zevacor Molecular, Navidea Biopharmaceuticals, Advanced Accelerator Applications, Blue Earth Diagnostics Limited, Bracco Diagnostic Inc., Lantheus Medical Imaging, Inc., Jazz Pharmaceuticals and many others significant players present worldwide.

Like it? Share it!


Aman Jaiswar

About the Author

Aman Jaiswar
Joined: May 14th, 2019
Articles Posted: 1,020

More by this author